CMV Disease in Stem Cell Transplantation: Prevention and Drug Resistance

TARGET AUDIENCE
This activity has been designed to meet the educational needs of physicians and clinical pharmacists involved in the treatment of hematopoietic cell transplant (HCT) recipients.

ACTIVITY PURPOSE
This activity is intended to assist physicians and pharmacists in preventing cytomegalovirus (CMV) infection in HCT recipients and implementing therapeutic strategies that reduce CMV drug resistance.

STATEMENT OF NEED
Cytomegalovirus (CMV) is an important cause of morbidity and mortality in recipients of hematopoietic cell transplant (HCT). CMV infection occurs in up to 60% of HCT patients, and CMV disease occurs in 10% of HCT patients in the preemptive therapy era.1,2 Immunosuppression before and after HCT causes patients to be particularly vulnerable to opportunistic infections such as CMV. The clinical manifestations of CMV disease range from gastrointestinal disease to life-threatening pneumonia, myelosuppression, retinitis, and encephalitis.
An understanding of the management of CMV, including prophylaxis and treatment, is especially important considering that many antiviral therapeutic agents have significant hematologic toxicity. Despite great progress in elucidating the pathophysiology of CMV infection and the spectrum of disease in HCT recipients, diagnostic and therapeutic challenges remain. Thus, it is clear that additional research and improved therapies are needed for this persistent pathogen.

1Razonable RR, et al. Expert Rev Anti
  Infect Ther. 2004;2:27-41.
2Nichols WG, et al. J Clin Virol. 2000; 16:
  25-40.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

  • Identify the changing epidemiology and clinical spectrum of disease caused by C. difficile
  • Describe the challenges associated with C. difficile infection in the long-term care setting
  • Identify optimal therapies in the treatment of C. difficile infection in the long-term care setting
  • Identify prevention and control measures that may contain the spread of CDAD

STATEMENT OF SUPPORT
This activity is jointly sponsored by Robert Michael Educational Institute LLC and Postgraduate Institute for Medicine, and is supported by an educational grant from ViroPharma Incorporated.


This continuing education monograph is accredited for physicians and pharmacists.
(Continuing education credit is no longer available for this activity.)


To Download PDF

  

   FACULTY
  

Michael J. Boeckh, MD
Associate Member
Program of Infectious Diseases
Vaccine and Infectious Disease Institute
Fred Hutchinson Cancer Research Center
Associate Professor
University of Washington School of Medicine
Seattle, WA
   
  

Sunwen Chou, MD
Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Oregon Health & Science University
Portland, OR


   CONTENTS

  • CMV Disease in Stem Cell Transplantation: Prevention and Drug Resistance

- Introduction
- Managing CMV in Hematopoietic Cell Transplant Recipients
  Michael J. Boeckh, MD
- CMV Drug Resistance: Clinical Impact and Potential Strategies
  Sunwen Chou, MD
- Summary
- References

  • Learning Assessment and Evaluation Form
 

 

Release Date:
   April 1, 2008
CE Available Until:
   April 1, 2009
Continuing education credit is no longer available for this activity.

© Copyright 2009. All rights reserved.
Developed and Managed by Robert Michael Educational Institute LLC
101 Laurel Road | Voorhees, New Jersey 08043 | www.RMEI.com | (866) 770-RMEI